JPMS-DTC
Active not recruiting
453 enrolled
ADONIS
Completed
554 enrolled
CCGLC-001
Recruiting
300 enrolled
A Clinical Study of Sorafenib Combined With Gefitinib for the Treatment of pNET
Recruiting
20 enrolled
STELLAR
Completed
335 enrolled
CCGLC-008
Recruiting
300 enrolled
ROCURS
Completed
4,103 enrolled
RIFTOS MKI
Completed
667 enrolled
Microvascular Invasion for Guiding Treatment of Barcelona Clinic Liver Cancer Stage B Hepatocellular Carcinoma
Unknown
200 enrolled
The Gut Microbiome and Sorafenib Maintenance Therapy in FLT3-ITD Positive AML After Allo-HSCT
Unknown
37 enrolled
The Gut Microbiome in FLT3-ITD+ AML Undergoing Allo-HSCT With Or Without Sorafenib Maintenance After Allo-HSCT
Unknown
60 enrolled
Influence of Co-existing Mutations on Sorafenib Maintenance Therapy After Allo-HSCT for Patients With FLT3-ITD AML
Completed
456 enrolled
Circulating Tumor Cells and Tumor DNA in HCC and NET
Completed
167 enrolled
Factors Affecting Post-treatment Outcomes in Patients With Hepatocellular Carcinoma
Completed
407 enrolled
SORAGO-HCC
Terminated
3 enrolled
Combined Immunotherapy and Targeted Therapy for Hepatocellular Carcinoma
Unknown
50 enrolled
Advanced Renal Cell Carcinoma, With Failure or Unsuitable on Prior Interferon-alpha or Interleukin-2 Based Therapy
Terminated
11 enrolled
OPTIMIS
Completed
1,676 enrolled
Nexavar Post-marketing Surveillance for Renal Cell Carcinoma in Japan
Completed
3,305 enrolled
Nexavar Post-marketing Surveillance for RCC in Japan: Early Access Program
Completed
117 enrolled
SANE
Completed
61 enrolled
SUCCESS
Completed
302 enrolled
Sorafenib in Elderly mRCC
Completed
60 enrolled
HCC Patient Preferences in Japan
Completed
120 enrolled
SECURE
Completed
106 enrolled
NEXST
Completed
205 enrolled
GIDEON
Completed
3,371 enrolled
Developing and Treating a Mouse Model of Acute Myeloid Leukemia Using Tissue Samples From Younger Patients With Acute Myeloid Leukemia
Completed
10 enrolled
STELLA
Completed
234 enrolled
SORINT
Completed
19 enrolled
Regulatory Post Marketing Surveillance Study on Nexavar®
Completed
2,845 enrolled
Profile of Soluble and Cellular Biomarkers and of Functional Imaging During Antiangiogenic Therapies in Cancer Patients
Terminated
60 enrolled
Nexavar Post-marketing Surveillance for Hepatocellular Carcinoma in Japan
Completed
1,637 enrolled
POWER-NEXT
Withdrawn
NEXTAR
Completed
20 enrolled
INSIGHT
Completed
791 enrolled
Hepatic Monitoring for Pazopanib
Completed
1 enrolled
Incidence, Prevalence, and Symptom Burden Associated With Advanced Renal Cell Carcinoma in Commercially Insured Population (Pharmetrics)
Completed
1 enrolled
Incidence, Prevalence, and Symptom Burden Associated With Advanced Renal Cell Carcinoma in Commercially Insured Population (IHCIS)
Completed
1 enrolled
PONDIAC
Completed
71 enrolled
Study of Combined Sorafenib With Radiotherapy in Patients With Advanced Hepatocellular Carcinoma
Unknown
45 enrolled
Combined Radiotherapy and Sorafenib in Patients With Hepatoma
Unknown
45 enrolled
SORHORM
Unknown
60 enrolled
Patient Characteristics in Advanced Renal Cell Carcinoma and Daily Practice Treatment With Nexavar
Completed
2,840 enrolled